SUMMARY OF PRODUCT CHARACTERISTICS

Similar documents
For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

Irish Medicines Board

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Health Products Regulatory Authority

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)

SUMMARY OF PRODUCT CHARACTERISTICS. Florgane 300 mg/ml Suspension for Injection for Cattle and Pigs

For the treatment and prevention of infections caused by:

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Doxivex, 100 mg/ml concentrate for oral solution for chickens and pigs

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

B. PACKAGE LEAFLET 1

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

SUMMARY OF PRODUCT CHARACTERISTICS

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

SUMMARY OF PRODUCT CHARACTERISTICS

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Ceftiocyl 50 mg/ml, suspension for injection for cattle and pigs

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

SUMMARY OF PRODUCT CHARACTERISTICS. CEFOKEL 50 mg/ml, suspension for injection for pigs and cattle

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)

EXCEDE Sterile Suspension

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. KARIDOX 100 mg/ml oral solution for use in drinking water for chickens and pigs [UK, ES, IT, NL, DK, RO]

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

B. PACKAGE LEAFLET 1

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Therios 300 mg and 750 mg Palatable Tablets for Dogs

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

Transcription:

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Oxycare 20 %w/v LA Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Oxytetracycline (Equivalent to Oxytetracycline Dihydrate 20.0% w/v 21.60% w/v) Excipients: Sodium Formaldehyde Sulphoxylate Dihydrate For a full list of excipients, see section 6.1 0.40 % w/v 3. PHARMACEUTICAL FORM Solution for injection A Clear amber solution. 4. CLINICAL PARTICULARS 4.1 Target species Cattle, sheep and pigs. Page 1 of 5

4.2 Indications for use, specifying the target species Oxycare 20/LA is specifically formulated to provide a prolonged action resulting in sustained antibacterial activity. Blood levels persist for at least 4 days. After administration by the intramuscular route maximum blood levels are achieved after 4 to 8 hours making Oxycare 20/LA suitable for the treatment of acute infections. Oxytetracycline has been shown to be effective in vitro against the following bacterial species: Bordetella bronchiseptica, Corynebacterium pyogenes, Erysipelothrix rhusiopathiae, Escherichia coli, Haemophilus somnus, Pasteurella haemolytica, Pasteurella multocida, Salmonella dublin, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus faecalis, Streptococcus pyogenes and Streptococcus uberis. Oxycare 20/LA is indicated in the treatment of: Atrophic rhinitis caused by Bordetella bronchiseptica, Pasteurella haemolytica and Pasteurella multocida; Navel/joint ill caused by Corynebacterium pyogenes, E. coli, and Staphylococcus aureus; Mastitis caused by Corynebacterium pyogenes, E. coli, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus uberis; Metritis caused by E. coli and Streptococcus pyogenes; Pasteurellosis and infections of the respiratory tract caused by Pasteurella haemolytica and Pasteurella multocida; Septicaemia caused by Salmonella dublin and Streptococcus pyogenes; Erysipelas caused by Erysipelothrix rhusiopathiae. Oxycare 20/LA can also be used in the control of enzootic abortion in sheep. 4.3 Contra-indications Not recommended for use in horses, dogs, cats. Not for use in animals suffering from hepatic or renal damage. 4.4 Special Warnings for each target species No special warnings. Page 2 of 5

4.5 Special precautions for use Special precautions for use in animals Do not dilute Oxycare 20 LA. If concurrent treatment is administered, use a separate injection site. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possiable, thearpy should be based on local (regional, farm level) epidermiological information about susceptibility of the target bacteria. Special precautions to be taken by the person administering the veterinary medicinal product to animals Take care to avoid accidental self-injection. Wash hands after use. In case of contact with eyes or skin, wash immediately with plenty of water as irritation may occur. 4.6 Adverse reactions (frequency and seriousness) Although the product is well tolerated, occasionally a slight local reaction of a transient nature has been observed. 4.7 Use during pregnancy, lactation or lay The use of tetracycline during the period of tooth and bone development, including late pregnancy may lead to tooth discoloration, Oxycare 20/LA can be safely administered to lactating animals. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route The recommended dose rate is 20 mg/kg bodyweight (i.e. 1 ml per 10 kg bodyweight) administered by deep intramuscular injection. The product is recommended for a single administration only. Maximum recommended dose at any one site: Cattle : 20ml Pigs : 10ml Sheep : 5ml Piglets : 1 day 0.2ml 7 days 0.3ml 14 days 0.4ml 21 days 0.5ml Over 21 days 1.0 ml/10kg 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary No treatment specified. Page 3 of 5

4.11 Withdrawal period Milk for human consumption must not be taken during treatment. Milk for human consumption may be taken from cows only after 10 days from the last treatment. Milk for human consumption may be taken from sheep only after 7 days from the last treatment. Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 31 days from the last treatment. Pigs may be slaughtered for human consumption only after 18 days from the last treatment. Sheep may be slaughtered for human consumption only after 9 days from the last treatment. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Antibacterials ATC Vet Code: QJ01AA06 5.1 Pharmacodynamic properties Oxytetracycline is a bacteriostatic antibiotic that inhibits protein synthesis in susceptible bacteria. Inside the cell it binds irreversibly to receptors on the 30S subunit of the bacterial ribosome where it interferes with the binding of the aminoacyl-transfer RNA to the acceptor site on the messenger RNA ribosome complex. This effectively prevents the addition of amino acids to the elongating peptide chain, inhibiting protein synthesis. Oxycare 20/LA is specifically formulated to provide a rapid and prolonged action resulting in sustained antibacterial activity. Blood levels persist for at least 4 days. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sodium Formaldehyde Sulphoxylate Dihydrate Magnesium Oxide light, Dimethylacetamide, Disodium Edetate Dihydrate, Ethanolamine (for ph adjustment), Water for injection. 6.2 Incompatibilities None Known. Page 4 of 5

6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years Shelf life after the first opening the immediate packaging: 28 days 6.4 Special precautions for storage Do not store above 25ºC. Protect from light. Following withdrawal of the first dose, use the product within 28 days. Discard unused material When the vial has been broached and the contents exposed to air, the solution may darken but the potency will be unchanged. 6.5 Nature and composition of immediate packaging Amber type II glass vials of 50 ml and 100 ml. Closed with nitrile rubber bungs with aluminium overseals. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Newry Co. Down, BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER(S) Vm: 02000/4156 9. DATE OF FIRST AUTHORISATION 30 th April 1998 10. DATE OF REVISION OF THE TEXT October 2008 DISTRIBUTED BY Animalcare Ltd 10 Great North Way York Business Park Nether Poppleton York YO26 6RB Page 5 of 5